Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-34DF5A1F-8307-456D-82C2-1B8E7E80B93F_4_en-US
DOI: https://doi.org/10.31003/USPNF_M5660_04_01
DOI Ref: 14v9c

© 2025 USPC Do not distribute

Apomorphine Hydrochloride

4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, hemihydrate, (R)-;

6aβ-Aporphine-10,11-diol hydrochloride hemihydrate CAS RN®: 41372-20-7; UNII: F39049Y068.

Anhydrous CAS RN®: 314-19-2; UNII: 9K13MD7A0D.

DEFINITION

Apomorphine Hydrochloride contains NLT 98.5% and NMT 101.5% of apomorphine hydrochloride (C₁₇H₁₇NO₂·HCl), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. Spectroscopic Identification Tests (197), Infrared Spectroscopy: 197K (CN 1-May-2020)
- B. IDENTIFICATION TESTS—GENERAL, Chloride (191)

Sample solution: 10 mg/mL of Apomorphine Hydrochloride in carbon dioxide-free water

Analysis: To 2 mL of the Sample solution add 0.1 mL of nitric acid. Mix, filter, and use the filtrate.

Acceptance criteria: Meets the requirements

ASSAY

• PROCEDURE

Sample solution: Dissolve 250 mg of Apomorphine Hydrochloride in a mixture of 5.0 mL of 0.01 N hydrochloric acid and 50 mL of alcohol. **Analysis:** Titrate the *Sample solution* with 0.1 N sodium hydroxide VS. Read the volume added between the first two points of inflexion. Each mL of 0.1 N sodium hydroxide is equivalent to 30.38 mg of apomorphine hydrochloride (C_{1.7}H_{1.7}NO₂·HCI).

Acceptance criteria: 98.5%-101.5% on the dried basis

IMPURITIES

• Residue on Ignition (281): NMT 0.1%

• ORGANIC IMPURITIES

Diluent: Glacial acetic acid and water (1:99)

Solution A: 1.1-g/L solution of sodium octanesulfonate, adjusted with diluted phosphoric acid (1:1) to a pH of 2.2

Solution B: Acetonitrile **Mobile phase:** See <u>Table 1</u>.

Table 1

| Time (min) | Solution A (%) | Solution B (%) |
|---------------|-------------------|-------------------|
| 0 | 85 | 15 |
| 2 | 85 | 15 |
| 32 | 68 | 32 |
| 37 | 68 | 32 |

Return to original conditions and re-equilibrate the system.

System suitability solution: 0.25 mg/mL each of <u>USP Apomorphine Hydrochloride RS</u> and boldine in *Diluent*. [Note—Boldine is 2,9-dihydroxy-

1,10-dimethoxyaporphine.]

Standard solution: 2.5 µg/mL of USP Apomorphine Hydrochloride RS in Diluent

Sensitivity solution: 0.14 μg/mL of <u>USP Apomorphine Hydrochloride RS</u> in *Diluent* from the *Standard solution*. [Note—The peak response of this solution is equivalent to that of a solution containing 1.25 μg/mL of morphine hydrochloride, taking into account the relative response

factor of this impurity (see <u>Table 2</u>).]

Sample solution: 2.5 mg/mL of Apomorphine Hydrochloride in Diluent

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm × 15-cm; 5-µm end-capped packing L1

Column temperature: 35° Flow rate: 1.5 mL/min Injection volume: $10 \text{ } \mu\text{L}$

System suitability

Samples: System suitability solution and Sensitivity solution

[Note—The typical relative retention times for boldine and apomorphine are about 0.9 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 2.5 between boldine and apomorphine, System suitability solution

Signal-to-noise ratio: NLT 10, Sensitivity solution

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of any individual impurity in the portion of Apomorphine Hydrochloride taken:

Result =
$$(r_{II}/r_{S}) \times (C_{S}/C_{II}) \times (1/F) \times 100$$

r,, = peak response of each impurity from the Sample solution

= peak response of apomorphine from the Standard solution

 $C_{\rm S}^{}$ = concentration of <u>USP Apomorphine Hydrochloride RS</u> in the *Standard solution* (mg/mL)

 C_{ij} = concentration of Apomorphine Hydrochloride in the Sample solution (mg/mL)

F = relative response factor (see <u>Table 2</u>)

Acceptance criteria: See <u>Table 2</u>. Disregard any peak below 0.05%.

Table 2

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|-------------------------------|-------------------------------|--------------------------------|------------------------------------|
| Morphine | 0.4 | 0.11 | 0.15 |
| Apomorphine | 1.0 | _ | - |
| Any other individual impurity | - | 1.0 | 0.10 |
| Total impurities | - | - | 0.5 |

SPECIFIC TESTS

• Optical Rotation, Specific Rotation (781S)

Sample solution: 10 mg/mL in Diluent

Diluent: 2.06-g/L solution of hydrochloric acid in water **Acceptance criteria:** -48° to -52°, determined at 20°

• Loss on Drying (731)

Analysis: Dry a sample at 105° for 2 h. **Acceptance criteria:** 2.0%-4.2%

Color of Solution

Sample solution: Place 100 mg of Apomorphine Hydrochloride in a suitable test tube, add 10 mL of cold, oxygen-free water, and agitate gently until dissolved.

Standard solution: Dissolve 5 mg of Apomorphine Hydrochloride in 100.0 mL of water. Transfer 1.0 mL of this solution to a test tube of the same size as that used for the *Sample solution*. Dilute with 6 mL of water, add 1 mL of a 50-mg/mL sodium bicarbonate solution, and then add 0.50 mL of iodine TS. Allow to stand for 30 s, add 0.60 mL of a 25-mg/mL sodium thiosulfate solution, and dilute with water to 10 mL.

Acceptance criteria: The color of the *Sample solution*, observed promptly after the Apomorphine Hydrochloride has dissolved, is not more intense than that of a color of the *Standard solution*.

ADDITIONAL REQUIREMENTS

- Packaging and Storage: Preserve in tight, light-resistant containers.
- <u>USP Reference Standards (11)</u>
 <u>USP Apomorphine Hydrochloride RS</u>

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

| Topic/Question | Contact | Expert Committee |
|----------------------------|--------------------------------------|---------------------------|
| APOMORPHINE HYDROCHLORIDE | Documentary Standards Support | SM32020 Small Molecules 3 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM32020 Small Molecules 3 |

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(2)

Current DocID: GUID-34DF5A1F-8307-456D-82C2-1B8E7E80B93F_4_en-US

DOI: https://doi.org/10.31003/USPNF_M5660_04_01

DOI ref: 14v9c